Purpose: Pancreatic cancer has limited options for early detection and this study tried to tackle that issue using TIDC (Time Intensity Density Curve), 3D volumetric and perfusion imaging. Experimental Design: This quantitative study was done by analyzing multi-phase CT images of patients undergoing treatment of different stages of pancreatic ductal adenocarcinoma (PDAC). Using advanced 3D imaging software we identified the perfusion and radiodensity of tumors at different stages. This analysis was done using 41 adult patients with unresectable treatment-naïve PDAC who were either enrolled in a clinical trial at HonorHealth Research Institute (Scottsdale, AZ) or treated at the City of Hope Comprehensive Cancer Center (Duarte, CA) as standard of care non study patients between 2015-2019. All patients were over the age of 18 and had been diagnosed with PDAC. We divided the participant sample into two groups, labeled Cohort 1 and Cohort 2. For image acquisition in both groups, we required to have multiphase CT images for the collection of images at both locations. Results: TIDC, 3D volumetric measurements and perfusion imaging proved useful in the quantification of tumor aggressiveness. Our results showed that perfusion in PDAC displayed delays in the venous phase which may be linked to vascular growth related activity and exhibits the active and viable part of the tumor. 3D volumetric analysis of the patient's multi-phase CT scan showed clear changes in arterial and venous perfusion and correlated with how rapidly patients progressed (e.g. tumor aggressiveness). Conclusion: TIDC and 3D volumetric analysis could play a significant role in defining the aggressiveness of the pancreatic ductal adenocarcinoma.
Citation Format: Syed Rahmanuddin, Derek Cridebring, Ron Korn, Jordyn Brase, Pejman Motarjem, Wenli Kai, Vincent Chung, Erkut Borazanci, Ajay Goel, Daniel Von Hoff. Role of Time intensity & density curve for detecting early changes in pancreatic adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT155.